Vivos Therapeutics (NASDAQ:VVOS) PT Raised to $6.60 at Ascendiant Capital Markets

Vivos Therapeutics (NASDAQ:VVOS) had its price objective upped by Ascendiant Capital Markets from $6.40 to $6.60 in a research note released on Tuesday morning, Marketbeat Ratings reports. The firm currently has a buy rating on the stock.

Vivos Therapeutics Price Performance

NASDAQ:VVOS opened at $2.71 on Tuesday. The firm has a market cap of $8.73 million, a price-to-earnings ratio of -0.25 and a beta of 7.74. The firm’s fifty day moving average price is $2.37 and its 200 day moving average price is $3.13. Vivos Therapeutics has a 1-year low of $1.91 and a 1-year high of $48.79.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Vivos Therapeutics stock. Armistice Capital LLC bought a new stake in Vivos Therapeutics, Inc. (NASDAQ:VVOS) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 57,000 shares of the company’s stock, valued at approximately $709,000. Armistice Capital LLC owned 4.29% of Vivos Therapeutics as of its most recent filing with the Securities & Exchange Commission. 26.35% of the stock is currently owned by institutional investors.

Vivos Therapeutics Company Profile

Vivos Therapeutics, Inc, a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring.